Tenax Therapeutics TENX 深 滬
等待開盤 04-30 09:30:00 美东时间
12.78
0.000
0.00%
華盛通- 最 高--
- 今 開--
- 成交量 0股
- 最 低 --
- 昨 收 12.78
- 總市值 32.94万
- 52周最高 18.38
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 5.34
- 委 比 0.00%
- 總股本 2.58万
- 歷史最高 274560.00
- 量 比 0
- 振 幅 0.00%
- 歷史最低 4.63
- 每 手 1
- 風險率 3.56%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Tenax Therapeutics appoints Thomas Staab as chief financial officer
Tenax Therapeutics (TENX) has appointed Thomas Staab as chief financial officer, effective May 11, 2026, replacing Thomas McGauley. Staab brings over 25 years of leadership experience across managemen...
04-22 19:38
Tenax Therapeutics names new CFO
Tenax Therapeutics (TENX) appointed Thomas R. Staab II as CFo, effective May 11, 2026, replacing interim CFO Thomas McGauley. Staab brings more than 25 years of financial leadership experience in the ...
04-22 19:18
Tenax Therapeutics Files Prospectus For Offering $300M Securities
https://www.sec.gov/Archives/edgar/data/34956/000165495426002661/tennx_s3.htm
03-24 23:44
美股大行评级 | 摩根大通上调哔哩哔哩至"超配"，目标价从27美元升至35美元；Rhythm遭花旗、大摩等多家机构下调目标价
今日重点评级关注：韦德布什：维持Black Diamond Therapeutic"跑赢大市"评级，目标价从13美元升至14美元；花旗：维持Olema Pharmaceuticals"买入"评级，目标价从60美元升至62美元
03-18 10:48
Cantor Fitzgerald Initiates Coverage On Tenax Therapeutics with Overweight Rating, Announces Price Target of $35
Cantor Fitzgerald analyst Olivia Brayer Saunders initiates coverage on Tenax Therapeutics (NASDAQ:TENX) with a Overweight rating and announces Price Target of $35.
03-17 20:40
美股大行评级 | 能源股获大行青睐！美国铝业、康索尔能源、康菲石油、EOG能源等获上调目标价；多只航空股遭下调目标价
今日重点评级关注：HC Wainwright & Co.：维持Altimmune"买入"评级，目标价从12美元升至25美元；BTIG：维持Jade Biosciences"买入"评级，目标价从28美元升至39美元
03-17 11:45
Tenax Therapeutics Q4 EPS $(0.38) Beats $(0.41) Estimate
Tenax Therapeutics (NASDAQ:TENX) reported quarterly losses of $(0.38) per share which beat the analyst consensus estimate of $(0.41) by 7.32 percent. This is a 111.11 percent decrease over losses of $(0.18) per share
03-10 19:18
Tenax Therapeutics Q4 net loss widens on higher R&D expenses
Tenax Therapeutics Q4 net loss widens on higher R&D expenses Overview U.S. pharmaceutical firm's Q4 net loss widened to $15.5 mln Company achieved randomization target in Phase 3 LEVEL study, topline data expected Q3 2026 Company initiated global Phase 3 LEVEL-2 trial and opened long-term OLE study
03-10 19:11
Tenax Therapeutics FY 2025 net loss rises 199% to USD 52.6 million
Tenax Therapeutics FY 2025 net loss rises 199% to USD 52.6 million Tenax reported a Q4 net loss of USD 15.54 million, up 148% from a year earlier. Q4 R&D expense rose 129% to USD 10.54 million, driven mainly by higher spending on the Phase 3 LEVEL trial and the global Phase 3 LEVEL-2 study, plus inc
03-10 19:04
BRIEF-Tenax Therapeutics Q4 Net Income USD -15.54 Million
BRIEF-Tenax Therapeutics Q4 Net Income USD -15.54 Million Mar 10 (Reuters) - Tenax Therapeutics Q4 operating expenses USD 16.449 million. Q4 operating income USD -16.449 million
03-10 19:00
